undamentalytics Newsletter
Sign in

Spero Therapeutics, Inc. income statement

In fiscal 2025, Spero Therapeutics, Inc. reported revenue of $66.8m, up 39.2% on the year before, operating income of $6.3m (a 9.5% margin) and net income of $8.6m, or $0.15 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0241891854104486747
Research and development2633346667654851973821
General and administrative711131621423626242120
Operating income−33−42−43−63−79−88−4221−7366
Income before tax−33−40−42−61−78−90−4625−699—
Income tax0000000300—
Net income−25−39−42−61−78−904623−6997
Diluted EPS−$11.98−$17.82−$2.60−$3.35−$3.52−$2.91−$1.23$0.43−$1.27$0.15$0.12
Diluted shares (average)2m3m16m18m22m31m38m53m54m59m60m
EBITDA−33−41−42−62−78−87−4122−736—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EDIT vs SPROSPRO vs STROOCUL vs SPRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Spero Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Spero Therapeutics, Inc.